An early-stage company based in the U.K. claims to have stabilized SARS-CoV-2 RNA for two months at 45 degrees Celsius. The research, by Stablepharma, in collaboration with University Hospital La Paz in Madrid, Spain, potentially paves the way for thermostable mRNA vaccines.
“It’s difficult to predict timelines,” says Özgür Tuncer, CEO, and executive director of Stablepharma. “But probably by 2022 we will be in a position to know if we can create a thermostable vaccine, and then it depends on a partnership [with a vaccine manufacturer].”
